[ACX 2024] Will the FDA or EMA withdraw approval of semaglutide for the treatment of obesity or diabetes in 2024?
Plus
49
Ṁ3746Jan 2
2%
chance
1D
1W
1M
ALL
Will the FDA or EMA withdraw approval of semaglutide for the treatment of obesity or diabetes in 2024?
Resolves the same as the original on Metaculus.
Resolution criteria
This question will resolve as Yes if either the US Food and Drug Administration or the European Medicines Agency withdraw approval for semaglutide (AKA Wegovy, Ozempic, or any other brand name for semaglutide) before January 1, 2025. The stated reason for withdrawal must include concerns of safety or harmful side effects.
Fine print and additional background information can be found on Metaculus.
Once the original resolves, its resolution will be applied to this market automatically. Trustworthy-ish users are encouraged to resolve this market before then if the outcome is known and unambiguous. Feel free to ping @jskf to request early resolution or to report issues.
This question is managed and resolved by Manifold.
Get
1,000
and3.00
Related questions
Related questions
Will aducanumab be withdrawn by the FDA by 2025?
47% chance
Will Ozempic / semaglutide be FDA-approved for Alzheimer's before 2030?
64% chance
The FDA will warn about overuse or misuse of semaglutide (Ozempic, Wegovy and Rybelsus) before the end of 2024.
23% chance
Will there be a recall of Wegovy/Ozempic before 2035?
80% chance
Will 10 million Americans be on semaglutide (or yet-to-be-approved equally good or superior alternatives) by the end of 2030?
78% chance
Will one of the GLP agonist drugs (eg Semaglutude/Wegovy Tirzepatide/Mounjaro) have a black box warning by 2025
33% chance
Will Retatrutide (new obesity drug) be FDA approved by the end of 2025?
46% chance
Will a GLP-1 agonist diabetes / weight loss drug be the top bestselling drug in 2025?
30% chance
Will a clinical trial reporting weight-loss benefits of a GLP-1 agonist be published in a major medical journal in 2024?
84% chance
[M$5k subsidy] Will any FDA-approved GLP-1 agonists be withdrawn from the market for safety reasons by...